TLT:CA:TSV-Theralase Technologies Inc. (CAD)

COMMON STOCK | Medical Devices |

Last Closing

USD 0.3

Change

-0.01 (-1.64)%

Market Cap

USD 0.07B

Volume

0.13M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
PINK:CA Perimeter Medical Imaging AI I..

+0.03 (+6.02%)

USD 0.05B
ASG:CA Aurora Spine Corp

+0.01 (+2.13%)

USD 0.03B
MDX:CA MedX Health Corp

N/A

USD 0.02B
NGMD:CA NuGen Medical Devices Inc

N/A

USD 0.02B
VPT:CA VentriPoint Diagnostics Ltd

+0.01 (+4.76%)

USD 0.02B
THRM:CA Therma Bright Inc

-0.01 (-12.50%)

USD 0.01B
EVMT:CA Evome Medical Technologies Inc..

+0.01 (+3.45%)

USD 0.01B
FREQ:CA Frequency Exchange Corp.

N/A

USD 0.01B
CNVI:CA Conavi Medical Corp.

-0.05 (-7.35%)

N/A

ETFs Containing TLT:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.21% 33% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.21% 33% F 67% D+
Trailing 12 Months  
Capital Gain 57.89% 100% F 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.89% 100% F 83% B
Trailing 5 Years  
Capital Gain -3.23% 40% F 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.23% 40% F 65% D
Average Annual (5 Year Horizon)  
Capital Gain 5.36% 50% F 57% F
Dividend Return 5.36% 50% F 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.55% 88% B+ 66% D+
Risk Adjusted Return 14.68% 50% F 63% D
Market Capitalization 0.07B 100% F 88% B+

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector